Recent FDA-approved drugs for the treatment of ccRCC include drugs that target effector pathways downstream of VHL such as the VEGF pathway (bevacizumab, sorafenib, sunitinib, pazopanib, axitinib) and the mTORC1 pathway (temsirolimus and everolimus) [9]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.